deCODE genetics
Corporate brand
UnclaimedAn Icelandic biopharmaceutical and human-genetics company that uses population-scale genomic, medical and genealogical data to discover disease mechanisms, biomarkers and drug targets.
Last updated October 14, 2026
Overview
deCODE genetics is a biopharmaceutical and human-genetics company headquartered in Reykjavík, Iceland. Founded in 1996 by neurologist and geneticist Kári Stefánsson, the company was established around an ambitious proposition: that the genetic factors contributing to common, complex diseases could be identified by studying an entire population at industrial scale rather than relying mainly on small families or isolated clinical cohorts. Its research combines DNA data, medical records, health information, phenotypic measurements and unusually comprehensive genealogical relationships among Icelanders. Iceland was selected as the company’s principal research setting because its relatively small and genetically well-characterized population, modern health system and extensive historical records offered an unusual basis for population genetics. deCODE built partnerships and databases that allowed researchers to connect biological samples with disease status and family relationships while using encryption and other safeguards to separate research data from personal identity. Participation in research has been voluntary, and the company has reported exceptionally high participation rates. By the late 2010s, more than two-thirds of Iceland’s adult population had participated in at least one research effort, while tens of thousands of participants had undergone direct genome sequencing. The company’s early strategy relied on family structures and microsatellite markers to locate genomic regions associated with disease. It later adopted high-throughput SNP genotyping, statistical imputation and whole-genome sequencing. These capabilities enabled deCODE to conduct genome-wide association studies and to identify variants associated with Alzheimer’s disease, cardiovascular conditions, cancer, diabetes, psychiatric disorders and numerous traits. Its work has also contributed to research on drug response, cognition, pigmentation and other human characteristics. The company’s findings are generally published in peer-reviewed scientific journals and have been used by academic researchers, pharmaceutical companies and precision-medicine programs. A central asset is deCODE’s genealogy infrastructure. In partnership with the Icelandic software company Fridrik Skúlason ehf, deCODE helped develop a computerized genealogy database covering Icelandic records across many generations. A public-facing version, Íslendingabók, allows eligible users to explore family relationships, while a protected research version supports genetic analysis without directly exposing participant identities. The combination of genealogy, genomic data and medical information enables researchers to reconstruct inheritance patterns and statistically extend sequencing information across related individuals. The company also became a prominent participant in the debate over commercial use of national health information. In the late 1990s, Iceland authorized the creation of a proposed Icelandic Health Sector Database containing copies of health records. The project attracted support as well as strong criticism from privacy advocates and bioethicists, particularly because of its commercial purpose and proposed opt-out structure. Although the database was never built, the controversy made deCODE an international case study in the ethical, legal and political challenges of population-scale biomedical research. deCODE experienced financial difficulties during the global biotechnology downturn and filed for bankruptcy protection in 2009. It emerged from the process after restructuring and was acquired by Amgen in 2012. Since becoming an independent Amgen subsidiary, deCODE has continued to operate as a genomics discovery organization rather than as a conventional consumer-testing brand. Its discoveries have supported the identification and validation of therapeutic targets and have contributed to drug-development programs, including work relevant to cardiovascular disease and ot…
History
deCODE genetics was founded in 1996 by Kári Stefánsson after he left an academic position in the United States to establish a genomics enterprise in Iceland. The company’s foundational idea was that common diseases such as cardiovascular disease, diabetes and psychiatric disorders could have discoverable genetic components, but that those components would require population-scale data, sophisticated statistical analysis and detailed knowledge of family relationships. Iceland provided an unusual environment for this model. The country had a relatively small population, extensive genealogical records, a national health system and a high degree of public familiarity with family history. deCODE began collecting DNA samples and health information from volunteers, while developing computerized genealogies and privacy mechanisms intended to permit data linkage without making research identities directly visible. Early work used microsatellite markers and family-based analysis to locate regions of the genome associated with disease. The company also entered into a major pharmaceutical partnership with Roche during its early development. The proposed Icelandic Health Sector Database became the company’s first major ethical and political controversy. Legislation passed in 1998 enabled a company to build a nationwide database of health records for research and health-system purposes, and deCODE was granted the right to create it after a public process. Supporters viewed the project as an opportunity to improve medicine and exploit Iceland’s distinctive data resources. Critics objected to its commercial structure, the proposed use of records unless individuals opted out, and the possibility that citizens could lose control over sensitive information. The database was never constructed, but the dispute placed deCODE at the center of international discussions about genomic privacy and public participation. During the late 1990s and early 2000s, deCODE expanded its disease programs and published genetic findings in major scientific journals. Its genetic map of the human genome, published in 2002 using thousands of microsatellite markers and Icelandic genealogical information, helped improve the ordering and accuracy of the public reference genome. The company also helped create Íslendingabók, a public genealogy service launched in 2003. Its research genealogy, kept under privacy controls, became an important analytical layer linking participants and relatives across generations. The arrival of SNP genotyping chips in the mid-2000s transformed deCODE’s work. The company could scan hundreds of thousands of common genetic variants and conduct genome-wide association studies across large groups of cases and controls. Statistical phasing and imputation allowed measured variants to be inferred across related individuals, increasing the effective power of studies. deCODE reported findings involving Alzheimer’s disease, coronary artery disease, stroke, atrial fibrillation, type 2 diabetes, schizophrenia, cancer and many other conditions and traits. The company encountered financial problems during the global financial crisis and filed for bankruptcy protection in 2009. After restructuring, it was acquired by Amgen in 2012. The acquisition gave Amgen access to deCODE’s genetics platform and discovery capabilities while allowing deCODE to retain a distinct scientific identity. Since then, deCODE has expanded its use of whole-genome sequencing and has continued publishing research based on Icelandic population data. Directly sequenced genomes, imputed data and medical phenotypes have enabled increasingly detailed studies of rare variants and disease mechanisms. By the late 2010s, participation in deCODE research exceeded two-thirds of Iceland’s adult population, and the company had sequenced tens of thousands of individuals. Its work became an influential model for national genome initiatives, precision medicine and pharmaceutical genetics. The company’s history therefore combines scientific innovation with persistent questions about consent, privacy, governance and the appropriate boundaries of commercial involvement in public-health research.
- 2019
Research participation reaches national scale
[1]More than two-thirds of Iceland’s adult population had participated in deCODE research, illustrating the scale of its population approach.
- 2015
Expansion of whole-genome sequencing research
[1]Results from large-scale Icelandic whole-genome sequencing and imputation projects added rare-variant resolution to the company’s population-genetics platform.
- 2012
Acquired by Amgen
[1]Amgen acquired deCODE, which became an independent subsidiary within the pharmaceutical company.
- 2009
Bankruptcy protection and restructuring
[1]deCODE entered bankruptcy protection amid financial difficulties and subsequently reorganized its operations.
- 2003
Íslendingabók launches
[1]The company launched a public genealogy database allowing eligible Icelanders to explore family relationships.
- 2002
Genetic map of the human genome
[1]deCODE published a large microsatellite-based genetic map that helped improve the ordering and accuracy of the human reference genome.
- 1998
Health Sector Database legislation
[1]Iceland passed legislation permitting creation of a national health-sector database, triggering a lasting debate over privacy, consent and commercial research.
- 1997
Genealogy development partnership
[1]deCODE partnered with Fridrik Skúlason ehf to accelerate development of a comprehensive computerized genealogy of Iceland.
- 1996
Company founded in Iceland
[1]Kári Stefánsson established deCODE genetics in Reykjavík with the goal of using population-scale genetic research to study common diseases.
Products and positioning
A population-genetics discovery company that integrates Icelandic genealogy, genomic data and health information to identify disease biology, genetic risk factors and therapeutically relevant targets.
Genomics research · 1996
Population genetics research platform
deCODE’s core platform integrates DNA samples, whole-genome sequencing, genotyping, medical information, phenotypes and genealogical relationships. It is designed to identify variants associated with disease and human traits, estimate inherited risk and reveal biological pathways that may be relevant to therapeutic development.
Drug discovery and biomarkers · 1996
Disease genetics discovery programs
The company conducts research across cardiovascular, neurological, psychiatric, metabolic and cancer indications. Its studies seek disease-associated variants, protective variants, biomarkers and genetically supported drug targets, with findings made available through scientific publications and pharmaceutical collaborations.
Genealogy service · 2003
Íslendingabók
Íslendingabók is a public-facing genealogy database developed with Icelandic technology partners. Eligible users can investigate family relationships using extensive historical and contemporary records. The public service is distinct from the protected research systems used for genetic and medical analysis.
Genomic analysis · 2015
Whole-genome sequencing and imputation
deCODE combines directly sequenced genomes with genotyping and genealogical relationships to infer genetic variation across a much larger population. This approach supports studies of rare variants as well as common disease associations and increases the statistical power of population-based research.
Controversies
1998
Controversy over the Icelandic Health Sector Database
The proposed national database would have combined health records for research and commercial purposes under an opt-out framework. Privacy advocates and bioethicists challenged the project’s consent model, governance and commercialization of public-health information. Although deCODE received authorization to create the database, it was never built.
Marketing campaigns
- 2003Íslendingabók public genealogy launch
Iceland
deCODE introduced a public genealogy service that made the company’s population approach visible in everyday Icelandic life and created a direct channel for public engagement with genealogical data.
Outcome. The service became widely used and complemented the company’s protected research genealogy.
Brand decisions
2012
Join Amgen as an independent subsidiaryM&ABackground
Amgen sought to strengthen its human-genetics and target-discovery capabilities.
Action taken
Amgen acquired deCODE while retaining it as a distinct operating and scientific organization.
Aftermath
deCODE continued population-genetics research and contributed genetic evidence to pharmaceutical discovery programs.
2009
Restructure after bankruptcy protectionStrategyBackground
Financial pressure led the company to seek bankruptcy protection during the global biotechnology and financial downturn.
Action taken
deCODE reorganized its business and continued its genetics-discovery activities.
Aftermath
The restructured company was later acquired by Amgen.
1996
Adopt a population-scale genetics modelStrategyBackground
The company was founded on the view that genetic contributors to common diseases would be difficult to identify through small family studies alone.
Action taken
deCODE combined broad participation, national genealogies, medical information and high-throughput genetic analysis in Iceland.
Aftermath
The model produced a large body of disease-association research and became influential in precision medicine and pharmaceutical genetics.
Recent events
- 2012
Amgen acquires deCODE genetics[1]
M&A
Amgen acquired deCODE, which continued as an independent subsidiary and genetics-discovery organization within the pharmaceutical group.
- 2009
deCODE files for bankruptcy protection[1]
Bankruptcy
The company entered bankruptcy protection during a period of financial pressure in the biotechnology sector and subsequently restructured.
- 1996
deCODE genetics is founded in Iceland[1]
Other
Kári Stefánsson founded the company to apply population-scale genetics to common and complex diseases.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/decode-genetics · Editorial policy · How profiles are compiled